1. Home
  2. NCO vs SPRO Comparison

NCO vs SPRO Comparison

Compare NCO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NCO

Southern Cross Acquisition I Corp. Ordinary Shares

N/A

Current Price

$9.87

Market Cap

145.1M

Sector

N/A

ML Signal

N/A

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

N/A

Current Price

$1.22

Market Cap

71.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NCO
SPRO
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.1M
71.6M
IPO Year
2026
2017

Fundamental Metrics

Financial Performance
Metric
NCO
SPRO
Price
$9.87
$1.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
179.1K
1.3M
Earning Date
N/A
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
111.81
EPS
N/A
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$9.83
$1.08
52 Week High
$9.88
$3.08

Technical Indicators

Market Signals
Indicator
NCO
SPRO
Relative Strength Index (RSI) 62.86 35.20
Support Level $9.85 $1.10
Resistance Level N/A $1.29
Average True Range (ATR) 0.01 0.06
MACD 0.00 0.04
Stochastic Oscillator 57.14 46.67

Price Performance

Historical Comparison
NCO
SPRO

About NCO Southern Cross Acquisition I Corp. Ordinary Shares

Southern Cross Acquisition I Corp is a blank check company formed for the purpose of effecting into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: